Fulcrum therapeutics® reports recent business highlights and third quarter 2021 financial results

–on-track to initiate enrollment by year-end in phase 1b clinical trial of ftx-6058 in people with sickle cell disease–

FULC Ratings Summary

FULC Quant Ranking